Actavis Specialty Brands R&D investment in the fourth quarter increased $23.8 million due to higher in-licensing costs and increased costs related to our biosimilar product development. Actavis Specialty Brands selling and marketing expenses decreased by $1.2 million to $45.3 million in the fourth quarter, primarily due to lower promotional spending in the U.S., partially offset by higher commercial spending in Canada.
For the full year 2012, Actavis Specialty Brands segment net revenue increased 9 percent to $482.4 million, due to increased sales of Generess Fe® which was launched in the second quarter of 2011 and sales growth for key promoted products including Rapaflo® and Crinone® and the addition of Kadian®.
Actavis Specialty Brands segment adjusted gross margin for the full year 2012 was 76.1 percent, compared to 78.7 percent in 2011 as a result of product mix. Anda Distribution Segment InformationThree Months EndedTwelve Months EndedDecember 31, December 31,(Unaudited; $ in millions)2012201120122011Net revenue
776.2Operating expenses:Cost of sales
168.1214.6846.6652.7Selling and marketing
17.6%14.6%14.2%15.9%Anda Distribution segment net revenue for the fourth quarter 2012 decreased 19 percent to $203.9 million compared to $251.4 million in the fourth quarter 2011 due to lower chain sales offset by new product launches. Anda Distribution segment revenue consists only of sales of third-party products and excludes sales of Actavis' brand and generic products.
Anda Distribution segment gross margin increased 300 basis points to 17.6 percent in the fourth quarter 2012, prim
|SOURCE Actavis, Inc.|
Copyright©2012 PR Newswire.
All rights reserved